Parasma: YC S26 Startup Turning Brain Cells Into Compute (2026)
Parasma is a YC S26 biocomputing startup founded 2026 in San Francisco, writing algorithms that train human brain cells to work as living computer processors.
Parasma is a San Francisco biocomputing startup backed by Y Combinator's Summer 2026 batch. Founded by Sean Cole, it writes bio-ML algorithms that train living human neurons to perform computation, joining an emerging wetware field alongside Cortical Labs and FinalSpark. The company is pre-product and solo-founded as of mid-2026.
Parasma is a Y Combinator S26 startup founded in 2026 in San Francisco. It writes algorithms that train human brain cells to function as a computing substrate, part of the emerging biocomputing or wetware field. Founded by Sean Cole, Parasma is pre-product and pre-revenue, with no public funding amount disclosed beyond YC backing.
Founded: 2026 · HQ: San Francisco, CA, USA · Team: 1 (solo founder, pre-seed) · CEO: Sean Cole · Funding: Backed by Y Combinator (S26 batch, 2026); specific amount not publicly disclosed
About Parasma
Parasma is a biocomputing startup founded in 2026 in San Francisco, by Sean Cole, who spent the prior year building after leaving FaZe before starting Parasma and joining Y Combinator's Summer 2026 (S26) batch. The company's stated mission is to write the algorithms that turn brain cells into compute: rather than building silicon chips, Parasma develops the software layer that trains living human neurons to perform computational work. As of mid-2026 the company is listed on Y Combinator's directory as a single-person team, placing it at pre-seed, pre-product stage rather than a company with a shipped commercial platform. Parasma sits inside a fast-moving research category known as biocomputing or wetware computing, which trains clusters of living neurons, lab-grown or primary human tissue, to perform pattern recognition and simple decision tasks using far less energy than a silicon accelerator. Academic groups have shown human neurons on a chip learning to play simple games such as Doom, and a March 2026 PNAS study demonstrated biological neurons performing temporal pattern learning tasks previously handled by artificial neural networks. Parasma's stated contribution is the machine learning layer that trains and reads out these biological substrates, not the substrate itself. Because Parasma has not publicized a named commercial product, release date, or pricing model, this profile reflects the company at its earliest public stage: a YC-backed pre-seed startup with a one-line mission statement and a single founder. There is no public evidence of a beta program, an API, or a hosted neuroplatform comparable to offerings from more established players in the space. Two companies most often cited as commercial precedent are Cortical Labs, an Australian firm known for its CL1 biological computer built from lab-grown neurons, and FinalSpark, a Swiss company that opened a remote-access neuroplatform of living neurons to university researchers. Parasma has not disclosed how its approach differs technically from either, beyond its emphasis on the algorithm and training layer rather than the hardware substrate. Parasma's only disclosed funding source is Y Combinator, via the S26 batch investment. No further seed round, valuation, or additional investor has been publicly reported as of mid-2026, and no revenue model or go-to-market plan has been made public. Any funding total beyond the YC batch investment should be treated as unconfirmed until the company discloses a round. Sean Cole is the company's sole named founder and, by implication, its CEO, though Parasma has not published a leadership page, an executive team, or a board. Public records describe him as having built a prior venture referred to as "FaZe" before founding Parasma in 2026; beyond that, no further biographical detail or co-founder information is public. Parasma's mission framing is narrow: train human brain cells for compute. Unlike frontier AI labs that publish safety frameworks or red-team partnerships, Parasma has not published safety, ethics, or research disclosure documents as of mid-2026. Given the company works with living human neural tissue, public information about donor consent, IRB oversight, or bioethics review would be a natural addition to its profile once published. Competitively, Parasma enters a category still led by Cortical Labs and FinalSpark, both of which already offer some form of paid or research access to biological compute. Parasma's stated differentiation is its algorithm and training methodology rather than owning proprietary hardware, but with no published benchmark, paper, or demo as of mid-2026, that differentiation is asserted rather than demonstrated. No IPO signal, acquisition rumor, or infrastructure partnership has been publicly reported for Parasma. As a brand-new single-founder YC company, the near-term outlook is to ship a first demonstrable product or public research result; this profile should be refreshed once Parasma discloses a funding round, a named product, or additional team members.
Mission
Write the algorithms to turn brain cells into compute.
Products
- Parasma bio-compute algorithms (Biocomputing R&D (pre-product)): https://parasma.com/
Links
Frequently Asked Questions
What is Parasma and what does it do?
Parasma is a biocomputing startup founded in 2026 in San Francisco that writes algorithms to turn human brain cells into a computing substrate. It works in the emerging field known as biocomputing or wetware, which trains living neurons rather than silicon transistors to perform computation. The company was founded by Sean Cole and joined Y Combinator's Summer 2026 (S26) batch. As of mid-2026 Parasma is a single-founder, pre-product company with no named commercial platform yet publicly announced. Its focus, per its own site, is the training and readout algorithms rather than the biological hardware itself. Related academic work has shown living neurons learning simple games and temporal pattern tasks, giving a sense of what this substrate can already do. Parasma has not yet published a benchmark, paper, or product demo of its own.
Who founded Parasma and who is the CEO?
Parasma was founded in 2026 by Sean Cole, who is its sole publicly named founder. Public records describe Cole as having built a prior venture referred to as FaZe before starting Parasma. Parasma has not published a formal leadership page, so Cole is presumed CEO by default as the only named team member. No co-founders, president, CTO, or additional executives have been publicly disclosed as of mid-2026. The company is listed on Y Combinator's directory as a one-person team, consistent with a very early pre-seed stage. No board of directors or governance structure has been made public. Readers should treat this as an early-stage, single-founder snapshot rather than a settled leadership team.
How much funding has Parasma raised?
Parasma's only publicly disclosed funding source is Y Combinator, through its Summer 2026 (S26) batch investment. No additional seed round, follow-on investor, or valuation has been publicly reported as of mid-2026. The company has not disclosed a specific funding amount tied to its YC participation. No revenue, ARR, or customer contract has been publicly reported, consistent with a pre-product company. There is no IPO timeline, acquisition talk, or strategic investor disclosed. Because Parasma is a brand-new single-founder company, its funding profile should be treated as a starting point rather than a complete picture. Any figure beyond confirmed YC backing should be considered unverified until the company discloses it directly.
What products does Parasma make?
Parasma has not publicly announced a named commercial product as of mid-2026. Its website describes the company's purpose as writing the algorithms that turn brain cells into compute, which points to a software and training layer rather than a packaged hardware product. There is no public API, software development kit, or hosted platform comparable to what more established biocomputing companies already offer. No pricing, free tier, or enterprise offering has been disclosed. The company has not stated whether it plans to sell software, a hosted service, or license its training methods to hardware partners. Because the company is pre-product, this section will need to be updated once Parasma ships something demonstrable. For now, treat Parasma as a research and development stage effort rather than a company with a live product.
Where is Parasma headquartered and how big is the team?
Parasma is headquartered in San Francisco, California, in the United States. As of mid-2026, Y Combinator's own directory lists the company as a one-person team, meaning founder Sean Cole is currently its only publicly known member. There is no evidence of additional offices, international hubs, or remote hiring at this stage. No hiring surge, layoff, or restructuring is applicable to a team this size. The company has not published a careers page or open roles as of this writing. Given its size, all research, engineering, and business functions are presumably handled by the founder directly. This profile should be revisited once Parasma discloses any team growth.
What is Parasma's mission or research focus?
Parasma's stated mission, in its own words, is to write the algorithms that turn brain cells into compute. This places the company inside the broader research field of biocomputing or wetware computing, which trains living neurons to perform pattern recognition and simple decision-making tasks. The appeal of this approach is energy efficiency: biological neurons can perform certain learning tasks using a fraction of the power a silicon accelerator needs. Academic work in 2026, including a PNAS study on temporal pattern learning in biological neurons, supports the technical premise Parasma is building on. The company has not published its own research papers, benchmarks, or safety disclosures as of mid-2026. It also has not disclosed details on tissue sourcing, donor consent, or bioethics review, which would be expected given its stated focus. Readers interested in the safety and ethics of this space should look to peer-reviewed sources until Parasma publishes its own position.
Is Parasma compliant with SOC 2, GDPR, HIPAA?
Parasma has not published any compliance certifications, a trust center, or a security page as of mid-2026. No SOC 2, ISO 27001, GDPR, or HIPAA documentation is publicly available for the company. This is consistent with its stage: a single-founder, pre-product startup that has not yet shipped a customer-facing service requiring these certifications. No data retention policy, data processing agreement, or EU AI Act classification has been disclosed. Given that Parasma's work involves human biological tissue rather than only software, bioethics and human-subjects oversight would be the more relevant compliance category to watch for, though nothing has been published on that front either. Prospective partners or researchers should contact the company directly for any compliance or ethics documentation. This section should be updated as soon as Parasma publishes formal policies.
Who are Parasma's main competitors?
The two companies most often cited alongside Parasma in the biocomputing space are Cortical Labs, an Australian firm known for its CL1 biological computer built from lab-grown neurons, and FinalSpark, a Swiss company offering a remote-access neuroplatform of living neurons to researchers. Both of those companies already offer some form of paid or research access to their platforms, while Parasma has not yet shipped a public product. Parasma's stated differentiation is its focus on the algorithm and training layer rather than owning the biological hardware substrate itself. Without a published benchmark or demo, that differentiation is currently a claim rather than a demonstrated result. Other adjacent players include academic labs publishing biological neural network research, such as the group behind the 2026 PNAS temporal-learning study. As the biocomputing field is still young, the competitive set is likely to shift quickly over the next 12 months. This profile should be revisited as Parasma and its peers publish more concrete product and research comparisons.